Navigation Links
Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
Date:4/24/2008

SANTA MONICA, Calif., April 24 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that it has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"), one of the leading microbiology research institutes in the People's Republic of China. JSIM has several drugs currently undergoing clinical testing and has new products in its development pipeline. This acquisition is expected to add several new products to Aida Pharmaceutical Inc.'s existing line of products, thus diversifying its product mix and enabling the Company to increase its market share in the PRC pharmaceutical market.

The controlling interest in JSIM was acquired through two of Aida Pharmaceutical Inc.'s subsidiaries, namely Hangzhou Aida Pharmaceutical Co., Ltd. (which acquired a 43% equity interest) and Changzhou Fangyuan Pharmaceutical Co., Ltd. (which acquired a 55% equity interest).

JSIM is a national leader in microbiology with over thirty years of research history. It is located in Wuxi City in Jiangsu Province, has over thirty scientists and engineers that have completed over 200 research projects. Of these research projects, over twenty of them were developed as national-level key projects, as designated by the Chinese government. JSIM's research efforts have yielded numerous patents.

About Aida Pharmaceuticals, Inc.

Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, Inc., in operation since March 1999, is headquartered in Hangzhou, People's Republic of China with manufacturing, distribution and sales points throughout mainland China. Aida Pharmaceuticals, Inc. is GMP-certified in the People's Republic of China and ISO9002-certified for quality assurance and ISO14000 certified for ecologically-friendly practices.
For additional information, please visit http://en.aidapharma.com.

Contact Information:

Ashley Hull

(310) 450-9100 opt 1

ashley@leacapital.com

Broker Contact:

Chesapeake Group

(410) 825-3930

Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.


'/>"/>
SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
2. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
3. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
4. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
7. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
8. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
9. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
10. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
11. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House ... , has announced that University of Maryland School of ... MBA and University of Maryland Medical System President and ... the "Speaker,s Medallion," the highest honor given to the ... Delegates. Dean Reece and Mr. Chrencik ...
(Date:2/10/2016)... York (PRWEB) , ... February ... ... (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, ... for infectious diseases and cancer. , The Human Vaccines Project brings ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
Breaking Biology News(10 mins):